Emotion and Motivation in Patients With Psychosis

University Hospital, Strasbourg, France41 enrolled

Overview

Anhedonia and avolition reflect emotional and motivational disorders, respectively. However, if these disorders play a major role in the symptomatology of schizophrenia, their mechanisms remain poorly understood, and existing treatments are inefficient on these symptoms. The literature suggests that the impairment does not concern emotion or motivation per se, but rather their influence on cognition. This project aims at using recent advances in the fundamental domain to better understand the cognitive and neuronal mechanisms of the patients' alterations, and especially how emotion and motivation influence cognition in schizophrenia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

ElectroencephalogramOTHER

electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli

Cognitive tasksBEHAVIORAL

\- clinical scales and subjective assessments of emotional and motivational stimuli

subjective evaluation scalesBEHAVIORAL

\- clinical scales and subjective assessments of emotional and motivational stimuli

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia Exclusion Criteria: * addiction problem * invalidating visual sensory problems * neurological history * for the healthy volunteers: psychiatric history

Locations (1)

Unité INSERM 1114

Strasbourg, France

Outcomes

Primary Outcomes

Change in the amplitude of the CNV (Contingent Negative Variation) as a function of the primer displayed on the screen

Before each cognitive trial a primer will be displayed, which will be either neutral or convey emotion or motivation. The investigators will check whether this primer affects the subjects preparation by measuring the CNV, which is an evoked potential recorded with electroencephalography, and indexing preparatory effort.

Time frame: During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)

Secondary Outcomes

Change in the amplitude of the LPP (Late Positive Potential) as a function of the primer displayed on the screen

The investigators will check whether primers affect the subjects attention by measuring the LPP, which is an evoked potential recorded with electroencephalography, and indexing sustained attention.

Time frame: During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.